Immuneel is a company bringing breakthrough cancer treatment to India through cell, gene, and immunotherapy.

Immuneel

A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.

Eight Roads Ventures

F-Prime Capital

True North

Immuneel Therapeutics Pvt. Ltd.

Arun Anand, MD Board Director & COO Immuneel Therapeutics Pvt. Ltd. was invited to speak at the inaugural edition of the Bengaluru Pharma Summit (2024) on 21st June, Bengaluru organized by Express Pharma, a respected industry publication from The Indian Express Group. 

The session featured pharma leaders discussing and touching upon important aspects like need to focus and invest on building and training talent to drive progress in the pharma industry, skilled R&D talent, and cost-effective manufacturing as India Pharma’s competitive advantage & India’s pharma shift to becoming the 'Discovery Pharmacy of the World'. 

At the panel “Bengaluru: Powering innovation in India Pharma Inc”, Dr Anand and other panelists highlighted the conducive environment, stellar academic centers, risk appetite and resident talent within the city making it an innovation powerhouse for pharma and biopharma, and the new areas of cell and gene therapy. Dr Anand elaborated on Bengaluru’s unique ecosystem that enabled Immuneel flourish as a start-up in the cell & gene therapy space, as well as the challenges that need to be mitigated for many more healthcare start-ups to bring pharma/biotech innovation forward.
 
Immuneel started its pioneering journey with establishment in Bengaluru in 2019, building an innovation culture driven by inspirational leadership, out-of-the-box thinking and a collaborative mindset leading to its first product -Varnimcabtagene autoleucel (CD19 CAR-T) - being approved and ready for commercial access.

Under the theme, ‘Co-creating an ecosystem for pharma innovation’, the Bengaluru Pharma Summit brought together experts, thought leaders, and veterans from the industry and regulatory bodies providing an overview and assessment of the potential areas for influencing business performance with value generation and sustainability.

To know more about us, visit: www.immuneel.com

#BengaluruPharmaSummit2024 #paneldiscussion #leadershipsession #immuneel #expresspharma #gratitude #indiapharma #biopharma #cellandgenetherapy #innovationinhealthcare #startupindia 

Arun Anand, MD D A Prasanna Dr. Goutam Pujari Dr Manoj Kumar Singh Siddalingaswamy. C.A

Arun Anand, MD Board Director & COO Immuneel Therapeutics Pvt. Ltd. was invited to join an insightful panel discussion on the topic “Cell & Gene Therapy Development and Manufacture, Present & Future” at 4th Edition of the India Biopharma Leaders Conclave (IBLC), held at Le Meridien, Hyderabad, June 2024. 

Exploring the theme of “New Horizons in Biopharma, Biosimilars, & Biologics,” this session featured esteemed panelists who are pioneers in the field of cell and gene therapy and covered current landscape, challenges and innovations within the sector and future prospects of cell and gene therapy development and manufacturing. Dr. Arun Anand focused on highlighting the growing innovation in the field of cell & gene therapy, operational challenges and guidance on navigating regulatory landscapes and optimized manufacturing. He emphasized the importance of harmonizing regulatory requirements globally to expedite therapy development and innovation, especially for gene therapies.

The India Biopharma Leaders Conclave showcases renowned speakers and eminent leaders from around the world coming together to exaggerate the present to imagine a future where biopharma holding the promise of transforming millions of lives.

Immuneel has a pioneering journey in India from incorporation towards its first product approval for Varnimcabtagene autoleucel (CD19 CAR-T) within 4 years and looking forward to commercialization of var-cel reaching patients in need.

Read more: https://lnkd.in/gJQn-zU9

To know more about us, visit: www.immuneel.com

#immuneel #cellandgenetherapy #IBLC2024 #conference #paneldiscussion #leadership #immunotherapy #futureofmedicine #innovationinhealthcare #startupindia #bluetechmedia #mediacoverage #neosciencehub

Arun Anand, MD Dr Akhilesh Sharma - MD, FRCP(Liverpool)CClin((USA),CPV (U.K) Murali Addepalli PhD  Dr. Ananda Gopu PERUMAL, (Ph.D) Renjitha Gopurappilly

Exciting event: Immuneel Therapeutics Pvt. Ltd. is honoured to be awarded ‘CGCS Pioneer Award’ in Cell & Gene Therapy space at 5th International Cell & Gene Therapy China Summit (CGCS 2024), Nanjing, China, May 22-24, 2024. This international recognition validates our pioneering journey to advancing innovative cell therapies and impacting patient lives in unmet need.

Immuneel’s Head of Commercial & Market Access Rebu Ninan was invited to speak on the CAR-T development in India at the Plenary. While speaking on India's robust biotechnology sector, innovation and supportive policies that place the country as a pivotal player in the global CGT landscape, Rebu delved into the transformative potential of CGTs & shared Immuneel’s remarkable journey in India towards its first product approval for Varnimcabtagene autoleucel (CD19 CAR-T) in 4 years. In addition, as panelist at the insightful CXO panel discussion on Cell Therapy Commercialization and Cooperation, Rebu discussed the necessity of a patient-centric approach to bring these groundbreaking therapies from lab to market.

The CGCS platform in China brings insights from world-class speakers from large pharma, innovative biotech, regulators, and academia covering various topics related to innovative cell and gene therapy, affordability, and commercialization. 

Immuneel expresses its gratitude to CGCS for the recognition acknowledging our endeavours as a startup in the cell and gene therapy space. As Immuneel gets closer to commercialization of Var-cel, accessibility to value-based global medicines remain at the forefront of our strategy to ensure these life-changing therapies reach those in need.

To know more about us, visit: www.immuneel.com

#immuneel #recognition #awards #leadershipsession #cellandgenetherapy #CGCS2024 #conference #patientcentricity #scienceandtechnology #immunotherapy #futureofmedicine #innovationinhealthcare #startupindia #india #milestonemoments #gratitude

Kiran Mazumdar Shaw Kush Parmar, M.D., Ph.D. Dr. Siddhartha Mukherjee Arun Anand, MD Rebu Ninan Lakshmikanth Gandikota Giridhar Chenji Nalini Raju Yogananth Rajendran M.Pharm.RAC Nitha Paul Prachi Dubey

Congratulations to the four pioneering scientists in CAR-T cell therapy on winning the 2024 Warren Alpert Foundation Prize!

Award recipients:
- Renier Brentjens, Katherine Anne Gioia Endowed Chair of Medicine and deputy director of Roswell Park Comprehensive Cancer Center
- Zelig Eshhar, professor emeritus, the Weizmann Institute of Science, chair of Immunology, Division of Research & Development, Sourasky Medical Center, Israel
- Carl June, Richard W. Vague Professor in Immunotherapy, University of Pennsylvania Perelman School of Medicine
- Michel Sadelain, Stephen and Barbara Friedman Chair, founding director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center
 
The four scientists honored with this year’s Warren Alpert Foundation Prize have played key distinct and complementary roles in developing CAR T cells whose transformational discoveries and persistent work has led to the creation of chimeric antigen receptor (CAR) T cells, and a new pillar of treatment for patients with terminal illness and saving the lives of tens of thousands of people. CAR T cell-based approaches could eventually be used to treat solid tumors, as well as a variety of autoimmune diseases and other conditions.

Thank you, Carl June member of Immuneel’s Scientific Advisory Board, for your extraordinary and innovative contribution to the field of immunotherapies and your continuous support in shaping Immuneel’s research strategies since 2019 towards our purpose of affordable and accessible cell therapies everywhere. 
 
Best Wishes from Immuneel!

Read more: https://lnkd.in/dZ3uJAEj

#congratulations #breakthroughprize #cellandgenetherapy #recognition #awards #innovation #scientificadvisor #2024WarrenAlpertPrize #pioneers #immuneel

Kiran Mazumdar Shaw Kush Parmar, M.D., Ph.D. Dr. Siddhartha Mukherjee, Arun Anand, MD Carl June

Moment of Pride: Congratulations, Dr Siddhartha Mukherjee, our Board Director & Co-founder, Immuneel Therapeutics, for being elected to the National Academy of Medicine USA. 

Siddhartha Mukherjee’s induction into the National Academy of Medicine is a testament to his unparalleled dedication and rigor towards the research of immunotherapy for childhood cancers and discovery of tissue-resident stem cell. He is also a winner of Pulitzer Prize for General Non-Fiction book, “The Emperor of All Maladies: A Biography of Cancer,” and was nominated by Time as among the century’s 100 most influential books. His latest book “Song of the Cell” won the 2023 PROSE Award for Excellence in Biological and Life Sciences and the 2023 Chautauqua Prize.

Members of the National Academy of Medicine are chosen by their peers in recognition of their outstanding achievements, and our Co-founder Siddhartha Mukherjee is one of the 100 extraordinary members announced by the Academy. It is matter of pride for us at Immuneel to have Siddhartha Mukherjee as one of our co-founders, and under his leadership we reaffirm our commitment and dedication to the advancements of cancer treatment and creating a world where affordable and accessible cell therapies are available everywhere.

A big day for Dr Siddhartha Mukherjee & for Immuneel!
  
Dr. Siddhartha Mukherjee, Kiran Mazumdar Shaw, Kush Parmar, M.D., Ph.D.Arun Anand, MD

Read more: https://lnkd.in/gJwMVGHb

To know more about us, visit: www.immuneel.com

#congratulations #Nationalacademyofmedicine #NAMS #cellandgenetherapy #recognition #innovation #leadership #achievements #immuneeltherapeutics

In the news: CAR-T cell therapy has revolutionized the landscape of cancer treatment, offering a lifeline to patients who have exhausted conventional options. Immuneel Therapeutics Pvt. Ltd. is playing a pivotal role in creating an ecosystem to enable making such cancer-targeting global quality CAR-T cell therapies accessible to patients in India and beyond!

In this article published in Healthcare Executive, sharat damodar, Chairman - Oncology Services, Clinical Director - MSMC Senior Consultant & Head of Adult Haematology and BMT, and Principal Investigator of the IMAGINE study exemplifies a patient case from IMAGINE trial demonstrating the potential of CD19 CAR T-Cell therapy (Varnimcabtagene autoleucel) to provide durable remission in relapsed lymphoma with cell therapy. 

Immuneel Therapeutics Pvt. Ltd. partnered alongside Narayana Health and other hospitals for India's first industry sponsored phase 2 CAR-T clinical trial IMAGINE with excellent results that led to its approval in India and presentations on its excellent data in global and Indian medical conferences. 

Read this article on Narayana Health City Advances Cancer Care with Landmark CAR T-Cell Therapy Success: https://lnkd.in/dGeBFXEQ

To know more about us, visit: www.immuneel.com

#cellandgenetherapy #immunotherapy #cartcelltherapy #immuneel #narayanahealthcity #hematologicalmalignancies #cancertreatment #collaborationwins #changemakers #patientcentricity #breakthrough #advancements #futureofmedicine #innovationinhealthcare #imagine #clinicaltrial #unmetneed #accessibility #startupindia

Kiran Mazumdar Shaw Kush Parmar, M.D., Ph.D. Dr Siddhartha Mukherjee Arun Anand, MD sharat damodar Anil Kamat Nalini Raju

COM:IMMUNEEL

Immuneel

Analysis Not Available